Search clinical trials for: Previously untreated DLBCL

Total 4191 results

Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more
Regeneron Pharmaceuticals

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Spain, Korea, Republic of, Belgium, Austria, Thailand, Singapore, Italy, Turkey, France, Australia, Czechia, Poland, Chile, United Kingdom, Germany
University Hospital Southampton NHS Foundation...
AstraZeneca

Recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A)

Diffuse Large B Cell Lymphoma

United Kingdom
University of Rochester

Recruiting

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DLBCL

United States
National Cancer Institute (NCI)

Active, not recruiting

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
University Hospital Muenster
Bayer

Active, not recruiting

Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP)

Diffuse Large B Cell Lymphoma

Germany
Shanghai Institute Of Biological Products

Completed

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

Diffuse Large B-Cell Lymphoma

China
Hoffmann-La Roche

Completed

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
JHL Biotech, Inc.

Terminated

A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

China
University of Wisconsin, Madison

Completed

R-CHOP + GM-CSF for Previously Untreated LCL in Elderly

Lymphoma, Large B-Cell, Diffuse

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Diffuse Large B-cell Lymphoma
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (Hi-CHOP)

Diffuse Large B-cell Lymphoma
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

United States
BioNTech SE

Not yet recruiting

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer
Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
AbbVie

Not yet recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico
Institut für Klinische Krebsforschung IKF GmbH...
Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp...

Recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC)

Biliary Tract Cancer | HER2 Gene Mutation

Germany
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

United States, Australia
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-2)

Follicular Lymphoma (FL)

Spain, United States, Australia, Turkey, Thailand, United Kingdom, Taiwan, Belgium, Poland, Chile, Italy
Diwakar Davar
Immunocore Ltd

Not yet recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Uveal Melanoma

United States
Hoffmann-La Roche

Recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

Belgium, Korea, Republic of, China, Japan, Australia, United States, Italy, Spain, Taiwan, United Kingdom, Germany, France, Canada, Mexico, Poland, Turkey, Switzerland, Brazil, Argentina, Denmark
Samsung Medical Center

Not yet recruiting

An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

Prostatic Adenocarcinoma

Korea, Republic of
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

China
Latin American Cooperative Oncology Group
AstraZeneca

Not yet recruiting

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil (EDUR-BRA)

Extensive-stage Small-cell Lung Cancer

Brazil
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Italy, Poland, Spain, Czechia
Institute of Hematology & Blood Diseases Hospital

Recruiting

Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Peripheral T Cell Lymphoma | Epigenetic Repression

China
AstraZeneca

Not yet recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)

Diffuse Large B-Cell Lymphoma
Sun Yat-sen University

Recruiting

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
AstraZeneca

Recruiting

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Chronic Lymphocytic Leukemia

China
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Seagen Inc.
Merck Sharp & Dohme LLC; RemeGen Co., Ltd.

Recruiting

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Urothelial Carcinoma

United States, Canada, Australia, Singapore
Ruijin Hospital

Recruiting

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Follicular Lymphoma

China
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Breast Cancer

Korea, Republic of, United States, Israel, Denmark, Argentina, Mexico, Brazil, Germany, Peru, Poland, Spain, Taiwan, South Africa, Czechia, Italy, Australia, Hungary
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan
Institut für Klinische Krebsforschung IKF GmbH...
Charite University, Berlin, Germany; Roche Pharma AG; Hoffmann-La Roche; Arbeitsgemeinschaft... and other collaborators

Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (R-Pola-Glo)

Lymphoma, Large B-Cell, Diffuse

Germany, Austria
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, Canada, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Italy, Poland, Turkey, Sweden, Switzerland
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France

3

Subscribe